Published in Onco Targets Ther on April 12, 2017
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015) 11.89
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med (2010) 6.34
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med (2017) 4.67
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet (2016) 4.12
Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin (2014) 3.59
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity (2013) 2.86
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet (2016) 2.25
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med (2013) 2.13
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med (2015) 2.12
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. J Clin Oncol (2016) 1.96
Translational biology of osteosarcoma. Nat Rev Cancer (2014) 1.72
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ (2013) 1.60
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol (2016) 1.54
Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev Anticancer Ther (2009) 1.27
Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res (2014) 1.23
Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer (1996) 1.13
Cancer immunotherapy: the past, the present and the future. Immunol Cell Biol (2003) 1.06
Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol (2016) 1.05
Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. J Immunother (2015) 1.04
Dose-dense chemotherapy improves mechanisms of antitumor immune response. Cancer Res (2012) 0.99
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol (2017) 0.99
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. N Engl J Med (2016) 0.95
Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports. PLoS One (2016) 0.91
Microsatellite instability in pediatric high grade glioma is associated with genomic profile and differential target gene inactivation. PLoS One (2011) 0.89
Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Sci Rep (2016) 0.88
Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Dis (2015) 0.86
Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a "common language" for the new arena of cancer treatment. J Immunother Cancer (2016) 0.86
Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas. Med Oncol (2016) 0.83
Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer (2016) 0.83
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. J Clin Oncol (2016) 0.82
Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. Oncologist (2016) 0.82
Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2016) 0.82
Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas. Oncotarget (2016) 0.82
Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev (2016) 0.81
Immunotherapy of Childhood Sarcomas. Front Oncol (2015) 0.81
Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother Cancer (2016) 0.81
Current and Emerging Perspectives on Immunotherapy for Melanoma. Semin Oncol (2015) 0.80
Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma. J Hematol Oncol (2016) 0.80
Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. Clin Cancer Res (2015) 0.80
Aldesleukin in advanced renal cell carcinoma. Expert Rev Anticancer Ther (2004) 0.79
A new paradigm for tumor immune escape: β-catenin-driven immune exclusion. J Immunother Cancer (2015) 0.79
PD-L1 testing, fit for routine evaluation? From a pathologist's point of view. Memo (2016) 0.79
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors. Vaccines (Basel) (2016) 0.78
Dendritic cell vaccination in pediatric gliomas: lessons learnt and future perspectives. Front Pediatr (2013) 0.78
Quantification of plasma and bone marrow VEGF and angiopoietin-2 levels in pediatric malignancies. J Pediatr Hematol Oncol (2012) 0.77
PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance. Oncoimmunology (2015) 0.77
Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers. Pediatr Blood Cancer (2016) 0.77
Update on use of aldesleukin for treatment of high-risk metastatic melanoma. Immunotargets Ther (2015) 0.76
Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report. J Neurosurg Pediatr (2016) 0.76
Connections between constitutional mismatch repair deficiency syndrome and neurofibromatosis type 1. Clin Genet (2016) 0.76
New immunotherapeutic strategies for the treatment of neuroblastoma. Immunotherapy (2015) 0.76
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. Cancer Immunol Res (2016) 0.76
Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. J Neurooncol (2016) 0.76